Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

@article{Morgan2009TargetedTF,
  title={Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.},
  author={Todd M. Morgan and Theodore D. Koreckij and Eva Corey},
  journal={Current cancer drug targets},
  year={2009},
  volume={9 2},
  pages={237-49}
}
A large number of novel therapeutics is currently undergoing clinical evaluation for the treatment of prostate cancer, and small molecule signal transduction inhibitors are a promising class of agents. These inhibitors have recently become a standard therapy in renal cell carcinoma and offer significant promise in prostate cancer. Through an understanding… CONTINUE READING